

A novel missense mutation in the COL7A1 gene underlies epidermolysis

bullosa pruriginosa

Gary S. Chuang, Amalia Martinez-Mir, Hsin-Su Yu,* Feng-Yi Sung, § Rita Y. Chuang,

Peter B. Cserhalmi-Friedman and Angela M. Christiano[†] Departments of Dermatology and [†]Genetics & Development, Columbia University, College of Physicians and Surgeons, New York, USA; *Department of Dermatology, National Taiwan University, Taipei, Taiwan; §Department of Dermatology Jen-Ai Municipal Hospital, Taipei, Taiwan.

Short Title: *COL7A1* mutation in Epidermolysis Bullosa Pruriginosa **Corresponding author:** Angela M. Christiano, Ph.D. Department of Dermatology Columbia University, College of Physicians and Surgeons 630 West 168th Street VC-1526 New York, NY 10022, USA

New York, NY 10032, USA Tel. : 212 305 9565 Fax: 212 305 7391 Email: amc65@columbia.edu

Abbreviations: *COL7A1*, COL7A1 gene; DEB, dystrophic epidermolysis bullosa; DDEB, dominant dystrophic epidermolysis bullosa; EB, epidermolysis bullosa; PCR, polymerase chain reaction.

Keywords: COL7A1 gene, epidermolysis bullosa pruriginosa, mutation

Abstract

Epidermolysis bullosa (EB) pruriginosa is a subtype of dominant dystrophic epidermolysis bullosa (DDEB), characterized by severe pruritus and blistering localized to the extensor surface of the extremities. EB pruriginosa exhibits extensive clinical heterogeneity with variable expressivity and delayed age of onset. Mutations in the *COL7A1* gene, especially in glycine residues within of Gly-X-Y repeats, have been shown to cause this form of DDEB. Here, we report a novel *COL7A1* mutation in a Taiwanese pedigree with EB pruriginosa. Using polymerase chain reaction amplification and direct sequence analysis, we have identified a G-to-T transversion at nucleotide 7097 within exon 92 of *COL7A1*, converting a glycine residue to valine (G2366V). The mutation resides within a consecutive, uninterrupted 17 Gly-X-Y of the triple-helical domain of type VII collagen. Interestingly, the proband in our family also displayed elevated IgE levels, previously reported in some patients with this disorder. Our finding further implicates *COL7A1* mutation in the pathogenesis of EB pruriginosa and underscores the heterogeneous clinical symptoms of glycine mutations in DDEB.

Report

Dystrophic epidermolysis bullosa (DEB) is a collection of hereditary bullous disorders characterized by blistering, scarring, and nail dystrophy.¹ The fragility is attributed to scarcity, or even the complete absence of anchoring fibrils composed mainly of type VII collagen.¹ Autosomal dominant and recessive inheritance patterns, as well as sporadic cases of DEB have all been described.²⁻⁴ To date, several hundred pathogenetic mutations within the collagenous and noncollagenous domains of type VII collagen gene (*COL7A1*) have been identified in different forms of DEB.⁵⁻¹² One subtype of dominant dystrophic epidermolysis bullosa (DDEB) is EB pruriginosa associated with intense pruritus and nodular prurigo-like lichenified lesions localized mostly in the lower extremities and extensor forearms.² Specifically in EB pruriginosa, 13 mutations, 9 of which involve glycine substitution, have been reported in literature (Fig. 2).

Here, we have identified a two-generation EB pruriginosa kindred of Taiwanese descent (Fig. 1a). The proband is a 52-year old woman (II-8) who developed intense pruritic blisters in her lower extremities and extensor surface of both arms in her twenties. A detailed clinical description of her symptoms was reported previously in the Chinese

literature.¹³ Briefly, histology of biopsy showed a subepidermal cleft and mild perivascular mononuclear infiltration in the upper dermis. Upon electron microscopic

examination, the anchoring fibrils were found to be decreased in number and thinner than in normal control skin. Neither the parents nor the six other siblings of the index case developed any similar symptoms. Recently, at the age of 25 years, the son (III-1) of the proband developed similar pruritic blisters on both shins and extensor arms (Fig. 2b). Although the 22 year-old daughter of the proband (III-2) lacked blistering lesions, nail dystrophy, and other symptoms of the disease, she had reported localized pruritus on pretibial skin and not yet reached the age of onset of her mother and brother.

After obtaining informed consent, DNA was isolated from peripheral blood lymphocytes in individuals II-7, II-8, and III-1 and from buccal cells in individual III-2, using PureGene DNA Isolation Kit (Minneapolis, MN). PCR amplification of the genomic sequence of COL7A1 gene was performed with oligonucleotide primers and conditions described previously.⁶ The PCR products were directly sequenced using ABI Prism Big Dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems) and the ABI Prism 310 automated sequencing system. Sequencing of affected individuals (II-8 and III-1) revealed a heterozygous GT transversion in exon 92 of the COL7A1 gene at nucleotide position 7097 (Fig. 1c), leading to the conversion of a glycine residue (GGT) to a valine residue (GTT), designated G2366V. Although individual III-2 has not yet developed the blistering symptoms of EB pruriginosa, sequence analysis confirmed that she is a carrier of the missense mutation and thus predisposed to developing symptoms in the future. Mismatched PCR with a forward primer (5'-GAGCTC CTG TGA GCC AAT TC-3') and a reverse mismatch primer (5'-CTG GGT ACA CAT ACC TTG TAA-3') was

used to create a new recognition site for the restriction enzyme *Mae*III. Restriction digest of the mismatched PCR product confirmed the mutation in affected and carrier family members, and excluded the mutation from 33 unrelated, unaffected control individuals, thus arguing against it being a common polymorphism.

To date, the etiology of severe pruritus in EB pruriginosa is unknown. Several studies had implicated an elevated IgE level and immune predisposition to atopy in the pathogenesis of the pruriginosa phenotype.^{4,15} Interestingly, with no prior personal or family history of atopy, patient III-1 reported an episode of idiopathic atopic dermatitis in the extensor arms, waist, buttock, and pretibial areas immediately before the appearance of blisters on his pretibia. In accounting for pruritus in the family reported here, available blood chemistry of patient III-1 showed an elevated level of serum IgE (222 IU/milliliter; normal range 0-59 IU/milliliter), over three times the upper limit of normal range. Other causes of itching in III-1 have been ruled out, including thyroid dysfunction, uremia, and low ferritin levels. Our study supports the earlier observation by Mellerio et al⁴ which found serum IgE levels to be elevated in seven out of nine EB pruriginosa patients. The pathogenesis of pruriginosa phenotype is poorly understood and how the immune response may participate in the development of the phenotype remains to be elucidated.

The mutation in residue G2366 occurs in the midst of 17 consecutive uninterrupted Gly-X-Y repeats in the triple helical domain of COL7A1. The missense mutation G2366V would likely destabilize the essential triple-helix formation of the collagenous domain. Glycine substitution mutations have been previously reported in various subtypes

of DDEB, including the Pasini, Cockayne-Touraine, pretibial, and pruriginosa subtypes. 3,4,8-10 Interestingly, in the glycine residue 2366, one compound heterozygous patient with G2366S/G2063W mutations was diagnosed with recessive dystrophic EB,¹⁴ highlighting the importance of residue G2366 (<u>Fig. 2</u>). Similarly, a heterozygous glycineto-serine missense mutation (G2369S) in the adjacent Gly-X-Y repeat causes dominant EB pruriginosa (<u>Fig. 2</u>).⁴ This observation is consistent with the notion that the specific position of a glycine substitution within a particular helical block, rather than its position along the entire collagenous domain, might be more critical in determining its impact on the overall stability of the collagen protein, disease phenotype, and mode of inheritance.³

In summary, we report the identification of a novel missense mutation, G2366V, within a Gly-X-Y repeat of type VII collagen in a family diagnosed with epidermolysis bullosa pruriginosa. This result furthers our understanding of both the clinical and allelic heterogeneity displayed in this subtype of DDEB and extends the body of evidence implicating *COL7A1* gene mutations in epidermolysis bullosa pruriginosa.

Acknowledgements

The authors are grateful to the family for their participation in this study, and HaMut Lam for expert technical assistance. This work was supported in part by NIH R01 AR43602 (A.M.C.) and R03 AR47184 (P.B.C.). G.S.C. is a fellow of Howard Hughes Medical Institute-Medical Student Training Fellowship.

References

1 Uitto J, Christiano AM. Molecular genetics of the cutaneous basement membrane zone. Perspectives on epidermolysis bullosa and other blistering skin diseases. *J Clin Invest* 1992; **90**: 687-92.

2 McGrath JA, Schofield OM, Eady RA. Epidermolysis bullosa pruriginosa: dystrophic epidermolysis bullosa with distinctive clinicopathological features. *Br J Dermatol* 1994; **130**: 617-25.

3 Lee JY, Pulkkinen L, Liu HS, *et al.* A glycine-to-arginine substitution in the triplehelical domain of type VII collagen in a family with dominant dystrophic epidermolysis bullosa pruriginosa. *J Invest Dermatol* 1997; **108**: 947-9.

4 Mellerio JE, Ashton GH, Mohammedi R, *et al.* Allelic heterogeneity of dominant and recessive COL7A1 mutations underlying epidermolysis bullosa pruriginosa. *J Invest Dermatol* 1999; **112**: 984-7.

5 Christiano AM, Greenspan DS, Lee S, *et al.* Cloning of human type VII collagen. Complete primary sequence of the alpha 1(VII) chain and identification of intragenic polymorphisms. *J Biol Chem* 1994; **269**: 20256-62.

6 Christiano AM, Hoffman GG, Chung-Honet LC, *et al.* Structural organization of the human type VII collagen gene (COL7A1), composed of more exons than any previously characterized gene. *Genomics* 1994; **21**: 169-79.

Bruckner-Tuderman L. Hereditary skin diseases of anchoring fibrils. *J Dermatol Sci* 1999; **20**: 122-33.

8 Christiano AM, Ryynanen M, Uitto J. Dominant dystrophic epidermolysis bullosa: identification of a Gly-->Ser substitution in the triple-helical domain of type VII collagen. *Proc Natl Acad Sci U S A* 1994; **91**: 3549-53.

9 Christiano AM, Lee JY, Chen WJ, *et al.* Pretibial epidermolysis bullosa: genetic linkage to COL7A1 and identification of a glycine-to-cysteine substitution in the triplehelical domain of type VII collagen. *Hum Mol Genet* 1995; **4**: 1579-83.

10 Christiano AM, Morricone A, Paradisi M, *et al.* A glycine-to-arginine substitution in the triple-helical domain of type VII collagen in a family with dominant dystrophic epidermolysis bullosa. *J Invest Dermatol* 1995; **104**: 438-40.

11 Christiano AM, Anton-Lamprecht I, Amano S, *et al.* Compound heterozygosity for COL7A1 mutations in twins with dystrophic epidermolysis bullosa: a recessive paternal deletion/insertion mutation and a dominant negative maternal glycine substitution result in a severe phenotype. *Am J Hum Genet* 1996; **58**: 682-93.

12 Christiano AM, McGrath JA, Tan KC, *et al.* Glycine substitutions in the triplehelical region of type VII collagen result in a spectrum of dystrophic epidermolysis bullosa phenotypes and patterns of inheritance. *Am J Hum Genet* 1996; **58**: 671-81.

Kao JS, Sheu HM, Yu HY. Pretibial Epidermolysis Bullosa -- A Case Report.*Derm Sinica* 1988; 6: 175-183.

14 Hashimoto I, Kon A, Tamai K, *et al.* Diagnostic dilemma of "sporadic" cases of dystrophic epidermolysis bullosa: a new dominant or mitis recessive mutation? *Exp Dermatol* 1999; **8**: 140-2.

15 Yamasaki H, Tada J, Yoshioka T, et al. Epidermolysis bullosa pruriginosa

(McGrath) successfully controlled by oral cyclosporin. Br J Dermatol 1997; 137: 308-10.

16 Tamai K, Hashimoto I, Murai T*, et al.* Particular mutations in exon 85 of type VII collagen gene (COL7A1) induce severe itch: specific glycine substitutions for dominant forms of epidermolysis bullosa pruriginosa. *J Invest Dermatol* 1998; **111**: A509.

17 Jonkman MF, Moreno G, Oranje AP, *et al.* Unusual dominant dystrophic epidermolysis bullosa phenotype caused by a novel glycine substitution mutation in the type VII collagen gene (COL7A1). *J Invest Dermatol* 1998; **110**: A511.

18 Chen X, Li G, Zhu X. [Study on COL7A1 gene mutation in a epidermolysis bullosa pruriginosa family]. *Zhonghua Yi Xue Za Zhi* 2000; **80**: 869-71.

Murata T, Masunaga T, Shimizu H, *et al.* Glycine substitution mutations by different amino acids in the same codon of COL7A1 lead to heterogeneous clinical phenotypes of dominant dystrophic epidermolysis bullosa. *Arch Dermatol Res* 2000; **292**: 477-81.

Jiang W, Bu D, Yang Y, *et al.* A novel splice site mutation in collagen type VII gene in a Chinese family with dominant dystrophic epidermolysis bullosa pruriginosa. *Acta Derm Venereol* 2002; **82**: 187-91.

Legends for Figures

Figure 1 (a) Pedigree of a Taiwanese family with epidermolysis bullosa pruriginosa. Affected individuals are indicated by filled figures. <u>(b) Clinical appearance of individual</u> <u>III-1 showing clusters of vesicles and prurigo-like nodules on bilateral pretibial skin. (c)</u> DNA sequence from an unrelated, unaffected control individual and an affected individual (II-8) are shown. The arrows indicate nucleotide position 7097, which is mutated from Gto-T in the heterozygous sequence of affected and carrier individuals, resulting in the missense mutation G2366V.

Figure 2 Compilation of mutations in *COL7A1* resulting in EB pruriginosa (modified from Mellerio *et al*, 1999). G2366V described in this study is shown in bold. G1791E, 5532+1GA/7786delG, G2242R, 6863del16, G2369S, and G2713R (Mellerio *et al*, 1999); G2239D and G2242E (Tamai *et al*, 1998); G2037E (Jonkman *et al*, 1998); G2034R (Chen *et al*, 2000); G2028R (Murata *et al*, 2000), and 6899AG (Jiang *et al*, 2002). Compound heterozygote G2366S/G2063W resulted in recessive dystrophic epidermolysis bullosa (Hashimoto *et al*, 1999).









